UBS Maintains a 'Neutral' on Alexion Pharmaceuticals (ALXN); Raising Estimates on aHUS, Margins
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UBS maintains a 'Neutral' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target raised from $57 to $70.
UBS analyst says, "Following another strong quarter, we are revising our estimates to reflect continued growth in PNH, as well as potential margin expansion through the addition of aHUS and high-risk trans plant (which we had previously underappreciated). Mgmt continued to temper aHUS launch expectations, and we have downwardly revised our aHUS estimates to reflect a more gradual ramp. We continue to view aHUS as a blockbuster indication, with $1.0B in WW aHUS revenues expected by 2020. We are raising our 2012 EPS estimate to $1.74 from $1.62."
"Alexion a core holding in biotech, but valuation remains challenging: On balance, we view Alexion as one of the most fundamentally solid companies in biotech, with a strong growth profile, top-flight mgmt, and through its target orphan drug indications, defensive against most economic pressures. However, despite our positive bias, we would prefer to wait for pullbacks or additional pipeline clarity before recommending ALXN shares."
For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $66.76 yesterday.
UBS analyst says, "Following another strong quarter, we are revising our estimates to reflect continued growth in PNH, as well as potential margin expansion through the addition of aHUS and high-risk trans plant (which we had previously underappreciated). Mgmt continued to temper aHUS launch expectations, and we have downwardly revised our aHUS estimates to reflect a more gradual ramp. We continue to view aHUS as a blockbuster indication, with $1.0B in WW aHUS revenues expected by 2020. We are raising our 2012 EPS estimate to $1.74 from $1.62."
"Alexion a core holding in biotech, but valuation remains challenging: On balance, we view Alexion as one of the most fundamentally solid companies in biotech, with a strong growth profile, top-flight mgmt, and through its target orphan drug indications, defensive against most economic pressures. However, despite our positive bias, we would prefer to wait for pullbacks or additional pipeline clarity before recommending ALXN shares."
For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $66.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
